Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.90
-1.06 (-5.06%)
Feb 21, 2025, 4:00 PM EST - Market closed
Arrowhead Pharmaceuticals Analyst Ratings
Total Analysts
11
Consensus Rating
Buy
Price Target
$43.33
Upside
+117.74%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +302.01% | Feb 12, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $42 | Buy | Reiterates | $42 | +111.06% | Feb 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +201.51% | Feb 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +302.01% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +302.01% | Dec 20, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +201.51% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $80 | Strong Buy | Maintains | $60 → $80 | +302.01% | Dec 3, 2024 |
| Bernstein | Bernstein | Hold Maintains $27 → $24 | Hold | Maintains | $27 → $24 | +20.60% | Nov 29, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $62 → $45 | Buy | Maintains | $62 → $45 | +126.13% | Nov 27, 2024 |
| Citigroup | Citigroup | Hold Maintains $27 → $26 | Hold | Maintains | $27 → $26 | +30.65% | Nov 27, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +201.51% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +201.51% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +201.51% | Oct 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $62 | Buy | Reiterates | $62 | +211.56% | Oct 8, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $42 | Buy | Reiterates | $42 | +111.06% | Sep 26, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 9, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.